ArticleACS infectious diseases2020
Biosynthesis, Mechanism of Action, and Inhibition of the Enterotoxin Tilimycin Produced by the Opportunistic Pathogen
Open access · bronzeAbstract read
In one paragraph
Article in ACS infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.2field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 33 citations in OpenAlex.
- Recent advances and clinical relevance of microbiome dynamics in health and disease.Gut microbes · 2026Review
- The Quorum-Sensing Regulator SdiA ActivatesMicroorganisms · 2026Article
- Protein Engineering of Biosynthetic Enzymes Unlocks Libraries of Bioactive Tilimycin Analogs.ACS catalysis · 2025Article
- Leveraging chemical synthesis to discover metabolites from the gut microbiome.Annals of the New York Academy of Sciences · 2025Review
- An efficient lysate-based approach for biosynthesis of the pyrrolobenzodiazepine natural product tilimycin.Journal of biotechnology · 2025Article
- Bacterial small molecule metabolites implicated in gastrointestinal cancer development.Nature reviews. Microbiology · 2025Review
- Article
- Expanding the Substrate Selectivity of the Fimsbactin Biosynthetic Adenylation Domain, FbsH.ACS chemical biology · 2024Article
- Multi-adductomics: Advancing mass spectrometry techniques for comprehensive exposome characterization.Trends in analytical chemistry : TRAC · 2024Article
- DNA Adductomics: A Narrative Review of Its Development, Applications, and Future.Biomolecules · 2024Review
- Epidemiology and antimicrobial resistance of toxin-producingHealth science reports · 2024Article
- Expanding the substrate selectivity of the fimsbactin biosynthetic adenylation domain, FbsH.bioRxiv : the preprint server for biology · 2024Article
- Structural, biochemical and bioinformatic analyses of nonribosomal peptide synthetase adenylation domains.Natural product reports · 2024Review
- Klebsiella oxytoca inhibits Salmonella infection through multiple microbiota-context-dependent mechanisms.Nature microbiology · 2024Article
- Structural advances toward understanding the catalytic activity and conformational dynamics of modular nonribosomal peptide synthetases.Natural product reports · 2023Review
- Liquid Chromatography-Mass Spectrometry Screening of Cyclophosphamide DNA Damage In Vitro and in Patients Undergoing Chemotherapy Treatment.Chemical research in toxicology · 2023Article
- Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy.Molecular therapy oncolytics · 2023Article
- Nucleic acid adductomics - The next generation of adductomics towards assessing environmental health risks.The Science of the total environment · 2023Article
- Enterotoxin tilimycin from gut-resident Klebsiella promotes mutational evolution and antibiotic resistance in mice.Nature microbiology · 2022Article
- Phylogenetic analysis and characterization of arsenic (As) transforming bacterial marker proteins following isolation of As-tolerant indigenous bacteria.Archives of microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Evan M AlexanderDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Dale F KreitlerDepartment of Structural Biology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York 14203, United States.ORCID 0000-0003-4758-7913
Valeria GuidolinMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Alexander K HurbenDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Eric DrakeDepartment of Structural Biology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York 14203, United States.
Peter W VillaltaDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0002-0067-3083
Silvia BalboMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0002-7686-0504
Andrew M GulickDepartment of Structural Biology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York 14203, United States.ORCID 0000-0003-4238-7453
Courtney C AldrichDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0001-9261-594X
University of Minnesota · USUniversity at Buffalo, State University of New York · US
Funding
Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4MX-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6MTraining the Next Generation of Chemical BiologistsT32GM132029 · NIGMS · UNIVERSITY OF MINNESOTA · PI Erin Elizabeth Carlson, William Charles Krause Pomerantz · 2019 to 2026
$2.7MStructural Studies of Nonribosomal Peptide SynthesisR35GM136235 · NIGMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI GULICK, ANDREW M · 2020 to 2024
$2.0MThe Structural Basis for Modular Nonribosomal Peptide SynthesisR01GM116957 · NIGMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI GULICK, ANDREW M · 2016 to 2019
$1.5MiTC200 MicroCalorimetry Cell Control UnitS10OD017982 · OD · UNIVERSITY OF MINNESOTA · PI ALDRICH, COURTNEY C · 2014 to 2014
$94kNCI NIH HHS P30 CA077598NIGMS NIH HHS P41 GM103393NIGMS NIH HHS R01 GM116957NIGMS NIH HHS R35 GM136235NIGMS NIH HHS T32 GM132029NIH HHS S10 OD017982
Abstract
Tilimycin is an enterotoxin produced by the opportunistic pathogen
Indexed as
Bacterial ToxinsKlebsiella oxytocaBenzodiazepinesEnterotoxinsKineticsPyrrolesBacterial ToxinsBenzodiazepinesEnterotoxinsPyrrolestilimycinadenylationKlebsiella oxytocamicrobiomenonribosomal peptide synthetasepyrrolobenzodiazepinetilimycin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.